![Michael Buschle](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Buschle
Direttore/Membro del Consiglio presso
VICORE PHARMA HOLDING AB
Profilo
Michael Buschle was the founder of Intercell AG, serving as Chief Scientific Officer from 1997 to 2012.
Current jobs include Director at Vicore Pharma Holding AB since 2023 and Advisor at HBM Partners AG since 2017.
Former jobs include Independent Director at Y-mAbs Therapeutics, Inc. from 2017 to 2018 and Chief Scientific Officer at Glenmark Pharmaceuticals Ltd. Education includes a doctorate from the University of London.
Posizioni attive di Michael Buschle
| Società | Posizione | Inizio |
|---|---|---|
| VICORE PHARMA HOLDING AB | Direttore/Membro del Consiglio | 01/01/2023 |
Precedenti posizioni note di Michael Buschle
| Società | Posizione | Fine |
|---|---|---|
| YMAS THER | Direttore/Membro del Consiglio | 11/12/2018 |
Intercell AG
 Intercell AG Pharmaceuticals: MajorHealth Technology Manufactures drugs and medicines | Fondatore | 01/01/2012 |
HBM Partners AG
 HBM Partners AG Investment ManagersFinance HBM Partners invests in private and public companies located in India, China, North America and Europe. The firm focuses on biopharma, medtech, diagnostics and healthcare sectors. It provides financing for early, buyout and growth stage capital requirements with an investment size from USD 5 to 50 million. | Investitore di Private Equity | - |
| GLENMARK PHARMACEUTICALS LIMITED | Direttore Tecnico/Scientifico/R&S | - |
Formazione di Michael Buschle
Esperienze
Posizioni ricoperte
Attive
Inattive
Società nel listino
Aziende private
Relazioni
26
Relazioni di 1° grado
6
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Aziende private | 6 |
|---|---|
HBM Partners AG
HBM Partners AG Investment ManagersFinance HBM Partners invests in private and public companies located in India, China, North America and Europe. The firm focuses on biopharma, medtech, diagnostics and healthcare sectors. It provides financing for early, buyout and growth stage capital requirements with an investment size from USD 5 to 50 million. | Finance |
Intercell AG
Intercell AG Pharmaceuticals: MajorHealth Technology Manufactures drugs and medicines | Health Technology |
Glenmark Pharmaceuticals Ltd.
 Glenmark Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Develops and manufactures pharmaceuticals | Health Technology |
University of London
 University of London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vicore Pharma Holding AB
 Vicore Pharma Holding AB Pharmaceuticals: MajorHealth Technology Engages in research and development of drugs for lung diseases | Health Technology |
Y-mAbs Therapeutics, Inc.
 Y-mAbs Therapeutics, Inc. BiotechnologyHealth Technology Develops radioimmunotherapy and antibody-based oncology therapies for treating cancer | Health Technology |
